Macro Group Pharmaceuticals (Macro Capital) S.A.E reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was EGP 215.17 million compared to EGP 183.78 million a year ago. Net income was EGP 58.1 million compared to EGP 66.04 million a year ago. Basic earnings per share from continuing operations was EGP 0.1 compared to EGP 0.11 a year ago. Diluted earnings per share from continuing operations was EGP 0.1 compared to EGP 0.11 a year ago.
For the nine months, sales was EGP 520.3 million compared to EGP 417.14 million a year ago. Net income was EGP 129.45 million compared to EGP 106.8 million a year ago. Basic earnings per share from continuing operations was EGP 0.23 compared to EGP 0.18 a year ago. Diluted earnings per share from continuing operations was EGP 0.23 compared to EGP 0.18 a year ago.